LU90616B1 - Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene - Google Patents

Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene

Info

Publication number
LU90616B1
LU90616B1 LU90616A LU90616A LU90616B1 LU 90616 B1 LU90616 B1 LU 90616B1 LU 90616 A LU90616 A LU 90616A LU 90616 A LU90616 A LU 90616A LU 90616 B1 LU90616 B1 LU 90616B1
Authority
LU
Luxembourg
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
LU90616A
Other languages
English (en)
Inventor
Preston Charles Conrad
Merlyn Gerard Flom
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of LU90616B1 publication Critical patent/LU90616B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
LU90616A 1999-07-29 2000-07-28 Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene LU90616B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14618499P 1999-07-29 1999-07-29
US14764299P 1999-08-06 1999-08-06
US14982099P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
LU90616B1 true LU90616B1 (fr) 2007-06-08

Family

ID=27386367

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90616A LU90616B1 (fr) 1999-07-29 2000-07-28 Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene

Country Status (45)

Country Link
EP (1) EP1204655B1 (fr)
JP (1) JP2001048880A (fr)
KR (1) KR100733094B1 (fr)
CN (1) CN1138771C (fr)
AR (1) AR029176A1 (fr)
AT (2) ATE251151T1 (fr)
AU (2) AU6335500A (fr)
BE (1) BE1013410A3 (fr)
BR (1) BR0003211A (fr)
CA (1) CA2314685C (fr)
CO (1) CO5180572A1 (fr)
CZ (1) CZ300356B6 (fr)
DE (2) DE60005693T2 (fr)
DK (1) DK176771B1 (fr)
EG (1) EG24196A (fr)
ES (1) ES2208384T3 (fr)
FI (1) FI20001721A (fr)
FR (1) FR2798384B1 (fr)
GB (1) GB2352716A (fr)
GR (1) GR20000100264A (fr)
HK (1) HK1034962A1 (fr)
HR (1) HRP20000502B1 (fr)
HU (1) HUP0003005A2 (fr)
ID (1) ID26679A (fr)
IL (1) IL137552A (fr)
IT (1) IT1318659B1 (fr)
LT (1) LT4789B (fr)
LU (1) LU90616B1 (fr)
LV (1) LV12733B (fr)
MD (1) MD2335G2 (fr)
MX (1) MXPA00007462A (fr)
MY (1) MY120393A (fr)
NL (1) NL1015822C2 (fr)
NO (1) NO325594B1 (fr)
NZ (1) NZ506045A (fr)
PE (1) PE20010383A1 (fr)
PL (1) PL341748A1 (fr)
PT (1) PT102501A (fr)
SE (1) SE0002793L (fr)
SG (1) SG90737A1 (fr)
SI (1) SI20427B (fr)
SV (1) SV2002000134A (fr)
TR (1) TR200002205A2 (fr)
TW (1) TWI271403B (fr)
WO (1) WO2001009115A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757291A3 (fr) * 2000-05-08 2009-07-15 Eli Lilly & Company Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
AU2005200809B2 (en) * 2000-05-08 2006-05-11 Eli Lilly And Company Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof
CZ20023651A3 (cs) * 2000-05-08 2003-02-12 Eli Lilly And Company Stabilizované přípravky 6-hydroxy-3-(4-[2-(piperidin-1-yl)-ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen a jejich sole
BR0114792A (pt) * 2000-10-20 2003-08-12 Lilly Co Eli Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
US7834187B2 (en) * 2004-07-22 2010-11-16 Eli Lilly And Company Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
EP1853263A1 (fr) * 2005-02-11 2007-11-14 Eli Lilly And Company Préparations et méthodes pour le traitement de la dyslipémie
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
CN113325183B (zh) * 2021-06-01 2022-11-15 中国医学科学院北京协和医院 一种用于鉴别诊断em/fem的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
PE44597A1 (es) * 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
GR20000100264A (el) 2001-03-30
CZ300356B6 (cs) 2009-04-29
EP1204655A2 (fr) 2002-05-15
LT2000075A (lt) 2001-02-26
FR2798384B1 (fr) 2004-09-24
SE0002793L (sv) 2001-01-30
ITMI20001758A1 (it) 2002-01-28
HK1034962A1 (en) 2001-11-09
CA2314685C (fr) 2009-10-20
CZ20002717A3 (en) 2001-05-16
NO20003876D0 (no) 2000-07-28
TWI271403B (en) 2007-01-21
HU0003005D0 (en) 2000-10-28
SG90737A1 (en) 2002-08-20
SE0002793D0 (sv) 2000-07-28
CN1138771C (zh) 2004-02-18
KR100733094B1 (ko) 2007-06-27
DE10036855A1 (de) 2001-03-22
MD2335G2 (ro) 2004-06-30
NL1015822C2 (nl) 2004-08-04
SI20427A (sl) 2001-06-30
NZ506045A (en) 2002-02-01
GB0018636D0 (en) 2000-09-13
PT102501A (pt) 2001-01-31
KR20010049911A (ko) 2001-06-15
SI20427B (sl) 2009-04-30
BR0003211A (pt) 2001-03-13
AT502317A1 (de) 2007-02-15
DE60005693T2 (de) 2004-07-29
WO2001009115A3 (fr) 2001-08-16
SV2002000134A (es) 2002-06-07
MD20000161A (en) 2001-04-30
BE1013410A3 (fr) 2001-12-04
EP1204655B1 (fr) 2003-10-01
NL1015822A1 (nl) 2001-01-30
MY120393A (en) 2005-10-31
AU6335500A (en) 2001-02-19
EG24196A (en) 2008-10-14
FI20001721A (fi) 2001-01-30
AR029176A1 (es) 2003-06-18
LV12733B (lv) 2002-02-20
TR200002205A2 (tr) 2001-03-21
FI20001721A0 (fi) 2000-07-28
HRP20000502B1 (en) 2008-04-30
ATE251151T1 (de) 2003-10-15
WO2001009115A2 (fr) 2001-02-08
IL137552A (en) 2009-06-15
ID26679A (id) 2001-02-01
ES2208384T3 (es) 2004-06-16
JP2001048880A (ja) 2001-02-20
IL137552A0 (en) 2001-07-24
HRP20000502A2 (en) 2001-06-30
CN1283622A (zh) 2001-02-14
DE60005693D1 (de) 2003-11-06
MXPA00007462A (es) 2002-06-04
PL341748A1 (en) 2001-02-12
PE20010383A1 (es) 2001-04-05
DK176771B1 (da) 2009-08-03
NO325594B1 (no) 2008-06-23
NO20003876L (no) 2001-01-30
GB2352716A (en) 2001-02-07
LV12733A (lv) 2001-10-20
IT1318659B1 (it) 2003-08-27
DK200001150A (da) 2001-01-30
CA2314685A1 (fr) 2001-01-29
IE20000604A1 (en) 2001-04-04
FR2798384A1 (fr) 2001-03-16
HUP0003005A2 (hu) 2002-04-29
ITMI20001758A0 (it) 2000-07-28
CO5180572A1 (es) 2002-07-30
LT4789B (lt) 2001-05-25
AU779559B2 (en) 2005-01-27
AU4891100A (en) 2001-02-01
MD2335F2 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
LU90616B1 (fr) Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene
LU90617B1 (fr) Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-Y1)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene
IL155487A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
NO20025219L (no) Stabiliserte formuleringer av 6-hydroksy-3-(4-[2-(piperidin-1- yl)etoksy]fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofen og salter derav
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
DZ3059A1 (fr) Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3(4-Ä2-(piperldin-1-YL)ethoxyÜphénoxy)-2-(4-methoxyphenyl) benuzoÄbÜthiopène.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
ECSP003592A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO
ECSP003593A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO